ArticleInternational journal for equity in health2018
A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals.
Article in International journal for equity in health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The price and affordability of essential medicines, progress and regional distribution in China: a systematic review.Frontiers in pharmacology · 2023Pooled it
- Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.PharmacoEconomics - open · 2026Article
- Evaluation of availability and affordability of lung cancer drugs in Central China: a cross-sectional study.BMC health services research · 2026Article
- Local systems, local solutions: which factors drive essential medicine availability in public health facilities across Indonesia?BMJ global health · 2026Article
- A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025Article
- Medicine availability and affordability for paediatric cancers, China.Bulletin of the World Health Organization · 2025Article
- Longitudinal Trends in Medicine Supply, Price and Utilisation in Primary Care Facilities in Rural Southwestern China Under National Essential Medicines Policy (2012-2017): Disparities Across Facilities and Medicines.International journal of health policy and management · 2025Article
- Availability, price and affordability of anticancer medicines in Jiangsu Province, China: a cross-sectional survey study.Frontiers in public health · 2025Article
- Geographical and temporal variations in availability of national price negotiated novel anticancer drugs: a spatial statistical study based on two cross-sectional datasets in China.Frontiers in pharmacology · 2025Article
- Economic assessment of potential changes to essential medicines for diabetes in Uganda.PloS one · 2025Article
- Trends and disparity in the provision and consumption of essential medicines in China from 2016 to 2021: institutional, regional, and economic variations.Frontiers in public health · 2025Article
- Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years.Frontiers in public health · 2024Article
- Access to anticancer medicines in public hospitals of Northwestern China.Frontiers in public health · 2023Article
- Accessibility of essential anticancer medicines for children in the Sichuan Province of China.Frontiers in public health · 2022Article
- Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.Frontiers in public health · 2022Article
- Evaluating the Price, Availability, and Affordability of Essential Medicines in Primary Healthcare Institutions: A Mixed Longitudinal and Cross-Sectional Study in Jiangsu, China.Frontiers in public health · 2022Article
- Irrational Use of Medicine in the Treatment of Presumptive Asthma Among Rural Primary Care Providers in Southwestern China.Frontiers in pharmacology · 2022Article
- Retail pharmacy prescription medicines' availability, prices and affordability in Eswatini.African journal of primary health care & family medicine · 2021Article
- Article
- What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEssential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential medicines. Research about the initiation of National Essential Medicines Policy in Chinese secondary and tertiary hospitals is inadequate, and the long-term effect on access after the reform is still unknown. This study's objective was to investigate the access to essential medicines in mainland China's secondary and tertiary hospitals.
methodsData on the access to 30 essential medicines from China's National Essential Medicine List were obtained from China Medicine Economic Information database covering 396 secondary hospitals and 763 tertiary hospitals. We improved the standard methodology developed by the World Health Organization and the Health Action International to measure the availability, median price ratio (MPR) and the incidence of catastrophic drug expenditure (CDE).
resultsFive essential medicines had > 50% availability and the nationwide availability kept steady; availability of drugs in eastern regions of China was significantly higher than the central and western regions. The median MPR of 30 drugs nationwide kept steady approximately 5; MPR of drugs in the eastern regions was significantly higher than the central and western regions and the ratio of MPR of innovator brands to generics increased from 3.66 to 6.32 during the study period. The incidence of CDE caused by essential medicines decreased from 2011 to 2014; brand name medicines were more likely to cause CDE than generics and rural patients have a greater tendency to fall into CDE.
conclusionsAfter the implementation of National Essential Medicines Policy, the MPR of essential medicines was well controlled and became more affordable in the context of steady availability. This has highlighted the problems associated with region disparity and inequity between rural and urban areas in the delivery of essential medicines and sustainable mechanisms are needed to deepen the National Essential Medicines Policy in mainland China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.